BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, BioMarin Pharmaceutical Inc. currently loses $12.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
BioMarin’s adjusted EPS of $0.23 topped the -$0.08 estimate by $0.31, based on preliminary third fiscal quarter of 2026 results reported November 2, 2026, improving from -$0.16 a year ago. The company generated operating cash flow of about $576.6 billion for the quarter. Looking ahead, consensus for the next period calls for EPS of $1.61 on revenue of $1.135 billion.
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing therapies for severe rare disorders and other serious medical conditions. Its products serve genetically defined diseases, and the company generated $3.2 billion of revenue in FY2025. BioMarin trades on the NASDAQ under the ticker BMRN.
Today's Snapshot
BMRN closed 5% higher at 61.43, outperforming a weaker sector. Shares changed hands at about half as much again as its usual level.
Trading Volume
Above 10d avg 2.1M
3M
vs S&P 500 Today
Strong Outperformance
+5.25%
Updated: November 18, 2026 at 21:16 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$57.59 - $58.97Buy
- RSI (14)64.19Neutral
- Stochastic %K (14, 3, 3)87.89Sell
- MACD Level (12, 26)0.32Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.